CN113136419A - 融合基因突变的荧光定量pcr检测方法 - Google Patents
融合基因突变的荧光定量pcr检测方法 Download PDFInfo
- Publication number
- CN113136419A CN113136419A CN202110642037.4A CN202110642037A CN113136419A CN 113136419 A CN113136419 A CN 113136419A CN 202110642037 A CN202110642037 A CN 202110642037A CN 113136419 A CN113136419 A CN 113136419A
- Authority
- CN
- China
- Prior art keywords
- fusion gene
- fusion
- amplification
- quantitative pcr
- fluorescent quantitative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000004927 fusion Effects 0.000 title claims abstract description 52
- 238000001514 detection method Methods 0.000 title claims abstract description 51
- 238000003753 real-time PCR Methods 0.000 title claims abstract description 23
- 206010064571 Gene mutation Diseases 0.000 title claims abstract description 17
- 230000003321 amplification Effects 0.000 claims abstract description 30
- 238000003199 nucleic acid amplification method Methods 0.000 claims abstract description 30
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 27
- 238000006243 chemical reaction Methods 0.000 claims abstract description 15
- 230000035772 mutation Effects 0.000 claims abstract description 10
- 230000002194 synthesizing effect Effects 0.000 claims abstract description 4
- 238000011144 upstream manufacturing Methods 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 15
- 239000013614 RNA sample Substances 0.000 claims description 12
- 239000000523 sample Substances 0.000 claims description 11
- 238000012408 PCR amplification Methods 0.000 claims description 9
- 239000002299 complementary DNA Substances 0.000 claims description 7
- 238000004090 dissolution Methods 0.000 claims description 6
- 238000010839 reverse transcription Methods 0.000 claims description 6
- 230000015572 biosynthetic process Effects 0.000 claims description 5
- 238000003786 synthesis reaction Methods 0.000 claims description 5
- 101150023956 ALK gene Proteins 0.000 claims description 4
- 101150068690 eml4 gene Proteins 0.000 claims description 4
- 238000012772 sequence design Methods 0.000 claims description 4
- 238000007865 diluting Methods 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 238000003113 dilution method Methods 0.000 claims description 3
- 230000036438 mutation frequency Effects 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 238000000746 purification Methods 0.000 claims description 3
- 238000012795 verification Methods 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 239000012295 chemical reaction liquid Substances 0.000 claims 1
- 238000004458 analytical method Methods 0.000 abstract description 4
- 238000013461 design Methods 0.000 abstract description 3
- 230000009089 cytolysis Effects 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 238000012165 high-throughput sequencing Methods 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 3
- 238000007901 in situ hybridization Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 102100027100 Echinoderm microtubule-associated protein-like 4 Human genes 0.000 description 2
- 101000779641 Homo sapiens ALK tyrosine kinase receptor Proteins 0.000 description 2
- 101001057929 Homo sapiens Echinoderm microtubule-associated protein-like 4 Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- JJWKPURADFRFRB-UHFFFAOYSA-N carbonyl sulfide Chemical compound O=C=S JJWKPURADFRFRB-UHFFFAOYSA-N 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 238000012151 immunohistochemical method Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000003793 prenatal diagnosis Methods 0.000 description 1
- 238000002331 protein detection Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6858—Allele-specific amplification
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110642037.4A CN113136419A (zh) | 2021-06-09 | 2021-06-09 | 融合基因突变的荧光定量pcr检测方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110642037.4A CN113136419A (zh) | 2021-06-09 | 2021-06-09 | 融合基因突变的荧光定量pcr检测方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113136419A true CN113136419A (zh) | 2021-07-20 |
Family
ID=76816115
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110642037.4A Pending CN113136419A (zh) | 2021-06-09 | 2021-06-09 | 融合基因突变的荧光定量pcr检测方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113136419A (zh) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102719525A (zh) * | 2012-04-12 | 2012-10-10 | 厦门艾德生物医药科技有限公司 | 用于检测eml4-alk融合基因突变的引物、探针及检测试剂盒 |
CN103468813A (zh) * | 2013-09-17 | 2013-12-25 | 广州达健生物科技有限公司 | Eml4-alk融合基因荧光定量pcr检测试剂盒 |
CN103805684A (zh) * | 2012-11-09 | 2014-05-21 | 益善生物技术股份有限公司 | Eml4-alk融合基因检测的pcr引物、试剂盒和液相芯片 |
CN105229175A (zh) * | 2013-03-15 | 2016-01-06 | 雅培分子公司 | 用于扩增和测定rna融合基因变体的方法、区分它们的方法以及有关的引物、探针和试剂盒 |
CN106978497A (zh) * | 2017-04-26 | 2017-07-25 | 武汉友芝友医疗科技股份有限公司 | Eml4‑alk融合基因突变的检测引物、探针及检测试剂盒 |
CN109439751A (zh) * | 2018-11-13 | 2019-03-08 | 武汉康录生物技术股份有限公司 | 一种用于检测kiaa1549-braf融合基因的荧光原位杂交探针试剂盒 |
CN109706232A (zh) * | 2019-03-04 | 2019-05-03 | 合肥欧创基因生物科技有限公司 | 用于检测人类alk基因融合突变的引物、探针及试剂盒及其检测方法 |
-
2021
- 2021-06-09 CN CN202110642037.4A patent/CN113136419A/zh active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102719525A (zh) * | 2012-04-12 | 2012-10-10 | 厦门艾德生物医药科技有限公司 | 用于检测eml4-alk融合基因突变的引物、探针及检测试剂盒 |
CN103805684A (zh) * | 2012-11-09 | 2014-05-21 | 益善生物技术股份有限公司 | Eml4-alk融合基因检测的pcr引物、试剂盒和液相芯片 |
CN105229175A (zh) * | 2013-03-15 | 2016-01-06 | 雅培分子公司 | 用于扩增和测定rna融合基因变体的方法、区分它们的方法以及有关的引物、探针和试剂盒 |
CN103468813A (zh) * | 2013-09-17 | 2013-12-25 | 广州达健生物科技有限公司 | Eml4-alk融合基因荧光定量pcr检测试剂盒 |
CN106978497A (zh) * | 2017-04-26 | 2017-07-25 | 武汉友芝友医疗科技股份有限公司 | Eml4‑alk融合基因突变的检测引物、探针及检测试剂盒 |
CN109439751A (zh) * | 2018-11-13 | 2019-03-08 | 武汉康录生物技术股份有限公司 | 一种用于检测kiaa1549-braf融合基因的荧光原位杂交探针试剂盒 |
CN109706232A (zh) * | 2019-03-04 | 2019-05-03 | 合肥欧创基因生物科技有限公司 | 用于检测人类alk基因融合突变的引物、探针及试剂盒及其检测方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220246234A1 (en) | Using cell-free dna fragment size to detect tumor-associated variant | |
CA2983833C (en) | Diagnostic methods | |
AU2015242941B2 (en) | ncRNA and uses thereof | |
US20180051329A1 (en) | Alignment and variant sequencing analysis pipeline | |
CN105525357A (zh) | 一种测序文库的构建方法及试剂盒和应用 | |
JP2018531583A (ja) | 血漿dnaの単分子配列決定 | |
US20200024644A1 (en) | Systems and methods for combined detection of genetic alterations | |
CN106995836B (zh) | 二代测序样品前处理的引物和方法以及试剂盒 | |
CN107541561B (zh) | 提高母体外周血中胎儿游离dna浓度的试剂盒、装置及方法 | |
CN105039322B (zh) | Dna标签序列及测序文库构建方法和试剂盒 | |
WO2009021338A1 (en) | Alternative splicing gene variants in cancer detection | |
CN109837275B (zh) | 一种融合基因阳性对照标准品的制备方法 | |
CN112011615A (zh) | 用于人甲状腺癌基因融合试剂盒及检测方法 | |
CN105886605B (zh) | Pkd2基因突变检测的扩增引物及检测方法 | |
Szcześniak et al. | Towards a deeper annotation of human lncRNAs | |
CN112795654A (zh) | 用于生物体融合基因检测与融合丰度定量的方法及试剂盒 | |
CA3119980A1 (en) | Methods, compositions, and systems for improving recovery of nucleic acid molecules | |
CN113136419A (zh) | 融合基因突变的荧光定量pcr检测方法 | |
CN103215349B (zh) | 一种染色体特异位点的筛选方法及应用 | |
US20220362771A1 (en) | Use of droplet single cell epigenome profiling for patient stratification | |
JP2022506752A (ja) | がんを診断するための方法及び関連するキット | |
CN102140523B (zh) | 高通量测序模板的原位复制及其增加阅读长度的测序方法 | |
US20230399678A1 (en) | A method for single-cell nascent rna labeling and sequencing | |
JP2010259336A (ja) | プローブ | |
Soulette et al. | Nanopore sequencing reveals U2AF1 S34F-associated full-length isoforms |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information |
Inventor after: Xie Hongtao Inventor after: Luo Weiquan Inventor after: Quan Zhihui Inventor after: Wang Yongsi Inventor after: Wen Yunjie Inventor after: Chen Dan Inventor after: Yu Qinhan Inventor before: Xie Hongtao Inventor before: Luo Weiquan Inventor before: Wang Yongsi Inventor before: Wen Yunjie Inventor before: Chen Dan Inventor before: Yu Qinhan |
|
CB03 | Change of inventor or designer information | ||
CB02 | Change of applicant information |
Address after: 510663 room 525, building g, 31 Kefeng Road, Huangpu District, Guangzhou City, Guangdong Province Applicant after: Guangzhou huayinkang Medical Group Co.,Ltd. Address before: 510663 room 525, building g, 31 Kefeng Road, Huangpu District, Guangzhou City, Guangdong Province Applicant before: Guangzhou Huayin health care group Co.,Ltd. |
|
CB02 | Change of applicant information | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20211223 Address after: 510663 units 304-306 and 307-319, 3rd floor, zone a, Guangzhou Science and technology innovation base, No. 80, lanyue Road, Science City, high tech Industrial Development Zone, Guangzhou, Guangdong Applicant after: GUANGZHOU HUAYIN MEDICAL LABORATORY CENTER CO.,LTD. Applicant after: Guangzhou huayinkang Medical Group Co.,Ltd. Address before: 510663 room 525, building g, 31 Kefeng Road, Huangpu District, Guangzhou City, Guangdong Province Applicant before: Guangzhou huayinkang Medical Group Co.,Ltd. |
|
TA01 | Transfer of patent application right | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20210720 |